AC Immune stock surges on amended Lilly collaboration deal By Investing.com

AC Immune amended its licensing/collaboration with Eli Lilly, receiving a CHF10m upfront payment, an additional Phase 1 dosing milestone payment, and remaining eligible for >CHF1.7bn in development/regulatory/commercial milestones plus low-double-digit tiered royalties. Shares jumped 13.9% on the announcement; the company expects to start IND-enabling studies in H1 2026 and highlighted oral, brain-penetrant Morphomer Tau small molecules that target intracellular Tau. Leerink Partners maintained an Outperform rating and a $9 price target, calling the amendment validation of AC Immune’s Morphomer platform.

Analysis

The deal materially changes modality-level optionality in the Tau race: an orally bioavailable, brain‑penetrant small molecule shifts commercial and payer dynamics away from high-priced injectable antibodies toward a lower‑cost, broader‑access therapy if clinical efficacy is proven. That second‑order effect compresses peak revenue multiples for incumbent antibody developers more than it dilutes absolute addressable market size — think lower price per patient but higher penetration, which favors partners with commercialization scale and cost‑efficient manufacturing.

Clinical and regulatory risk remains the dominant value driver and the primary volatility engine. CNS target engagement and safety are binary and typically take 12–36 months to crystallize meaningfully; absence of convincing biomarkers or an adverse safety signal would rapidly reprice valuations despite partner validation. Conversely, clear early human PK/PD or brain exposure data would re‑rate modality perception across the sector and catalyze M&A or licensing arbitrage.

From a positioning perspective, the optimal exposure is asymmetric — capture validated upside while limiting the binary downside of CNS failures. The partnership de‑risks certain execution paths but doesn’t materially change the underlying probability of clinical success; therefore the trade should be event‑driven and capped. Additionally, watch for rising interest from large pharmas to buy platform access rather than internal discovery, which would create a compressed window for strategic M&A competition and drive takeover premiums for platform owners.

Key Decisions for Investors

• ACIU: Initiate a tactical, asymmetric exposure — buy a 12–18 month call spread sized at 0.75–1.5% NAV (long OTM LEAP call, sell a higher strike) to capture upside from early human PK/PD/IND milestones while capping premium spent. Target 2:1–3:1 reward:risk; trim half on a 60–80% gain, hard stop and close on a 40% drawdown or failure to file IND‑enabling studies within 12 months.
• Pair trade (modal hedge): Long ACIU equity (0.5–1% NAV) paired with a short position in a large Tau‑antibody exposed stock (e.g., BIIB) sized ~0.6% NAV to isolate modality/outcome exposure. Hold 12–24 months; unwind the short if antibody developers report superior outcomes or if ACIU shows negative CNS safety signals.
• LLY: Keep modest strategic exposure — buy 18–24 month LEAP calls sized 0.5% NAV as a hedge to capture potential upside to the partner if the small‑molecule approach validates; this is a lower‑volatility way to participate vs owning multiple small‑caps. Take profits on a 30–50% move; cap loss at 30%.
• Risk control: Limit total biotech asymmetric exposure from this theme to 3% NAV. Use protective puts or pre‑defined stops keyed to binary clinical/regulatory gates (IND filing, first‑in‑human PK readout, any serious CNS AE) and re‑evaluate position sizing after each gate clears.